Drug news
CHMP recommends Intuniv (guanfacine hydrochloride extended release) for ADHD
Shire plc announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of the once-daily, non-stimulant Intuniv (guanfacine hydrochloride extended release; GXR) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents. The CHMP’s positive opinion is based on results from three Phase III pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents with ADHD.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins